EP3755312A4 - Darreichungsformen und verfahren für enantiomer angereichertes oder reines bupropion - Google Patents

Darreichungsformen und verfahren für enantiomer angereichertes oder reines bupropion Download PDF

Info

Publication number
EP3755312A4
EP3755312A4 EP19756920.5A EP19756920A EP3755312A4 EP 3755312 A4 EP3755312 A4 EP 3755312A4 EP 19756920 A EP19756920 A EP 19756920A EP 3755312 A4 EP3755312 A4 EP 3755312A4
Authority
EP
European Patent Office
Prior art keywords
methods
dosage forms
enantiomerically enriched
pure bupropion
bupropion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19756920.5A
Other languages
English (en)
French (fr)
Other versions
EP3755312A1 (de
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axsome Therapeutics Inc
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of EP3755312A1 publication Critical patent/EP3755312A1/de
Publication of EP3755312A4 publication Critical patent/EP3755312A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19756920.5A 2018-02-23 2019-02-25 Darreichungsformen und verfahren für enantiomer angereichertes oder reines bupropion Pending EP3755312A4 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US201962809480P 2019-02-22 2019-02-22
PCT/US2019/019445 WO2019165379A1 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Publications (2)

Publication Number Publication Date
EP3755312A1 EP3755312A1 (de) 2020-12-30
EP3755312A4 true EP3755312A4 (de) 2022-03-16

Family

ID=67688503

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19756920.5A Pending EP3755312A4 (de) 2018-02-23 2019-02-25 Darreichungsformen und verfahren für enantiomer angereichertes oder reines bupropion

Country Status (18)

Country Link
EP (1) EP3755312A4 (de)
JP (3) JP2021513998A (de)
KR (3) KR20230075531A (de)
CN (1) CN112087999A (de)
AU (3) AU2019223187B2 (de)
BR (1) BR112020017179A2 (de)
CA (1) CA3092076A1 (de)
CL (1) CL2020002166A1 (de)
CR (1) CR20200415A (de)
EC (1) ECSP20060179A (de)
IL (2) IL313368A (de)
MA (1) MA51914A (de)
MX (2) MX2020008704A (de)
NI (1) NI202000056A (de)
NZ (1) NZ767378A (de)
PE (1) PE20211752A1 (de)
SG (1) SG11202008056SA (de)
WO (1) WO2019165379A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
WO2021055124A1 (en) * 2019-09-20 2021-03-25 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501890A (ja) * 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（＋）−ビュープロピオンの薬学的使用
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
MEP3608A (en) * 2003-08-08 2011-05-10 Biovail Lab Int Srl Modified-release tablet of bupropion hydrochloride
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US9198905B2 (en) * 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
WO2015095713A1 (en) * 2013-12-20 2015-06-25 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects

Also Published As

Publication number Publication date
CA3092076A1 (en) 2019-08-29
ECSP20060179A (es) 2020-12-31
AU2019223187A1 (en) 2020-09-17
IL276871B1 (en) 2024-07-01
NZ767378A (en) 2024-03-22
AU2022204521A1 (en) 2022-07-21
EP3755312A1 (de) 2020-12-30
MA51914A (fr) 2020-12-30
JP2024075655A (ja) 2024-06-04
JP2022153638A (ja) 2022-10-12
IL276871A (en) 2020-10-29
PE20211752A1 (es) 2021-09-06
SG11202008056SA (en) 2020-09-29
MX2023009281A (es) 2023-08-17
KR20230075531A (ko) 2023-05-31
AU2022204521B2 (en) 2024-09-05
KR20240091043A (ko) 2024-06-21
KR20210003091A (ko) 2021-01-11
JP2021513998A (ja) 2021-06-03
CN112087999A (zh) 2020-12-15
AU2024205858A1 (en) 2024-09-05
IL313368A (en) 2024-08-01
WO2019165379A1 (en) 2019-08-29
CR20200415A (es) 2021-02-03
AU2019223187B2 (en) 2022-07-28
CL2020002166A1 (es) 2020-10-23
BR112020017179A2 (pt) 2020-12-22
MX2020008704A (es) 2020-12-07
NI202000056A (es) 2021-01-11

Similar Documents

Publication Publication Date Title
EP3869985A4 (de) Zusammensetzung und verfahren zur behandlung der lungen
EP3733715A4 (de) Triabody, verfahren zu seiner herstellung und seine verwendung
EP3752231A4 (de) Verfahren und inhalator zur bereitstellung von zwei oder mehr substanzen durch inhalation
EP3665181A4 (de) Zusammensetzungen und verfahren zur entkolonisierung von antibiotikaresistenten bakterien im darm
EP3755312A4 (de) Darreichungsformen und verfahren für enantiomer angereichertes oder reines bupropion
EP3324975A4 (de) Zusammensetzung mit einem therapeutischen wirkstoff und einem respiratorischen stimulans und verfahren zu deren verwendung
EP3801552A4 (de) Zusammensetzung und verfahren zur inhalation
EP3507977A4 (de) Systeme und verfahren zur codierung und wiedergabe von panoramavideoinhalten
IL287905A (en) A pharmaceutical preparation containing brexanolone, gnaxolone or zoranolone and its use
EP3559133A4 (de) Beschichtungszusammensetzungssystem, herstellungsverfahren und verwendung davon
EP3429598A4 (de) Zusammensetzungen und verfahren zur behandlung von beta-catenin-assoziierter erkrankung oder störung
EP3406602A4 (de) 1-sulfonamido-4-aryloxyverbindung und herstellungsverfahren und medizinische anwendung davon
EP3351549A4 (de) Zusammensetzung, die reich an einzelisomer-nuc-1031 ist, und herstellungsverfahren und verwendung davon
EP3275454A4 (de) Pharmazeutische zusammensetzung mit silybin, ve und l-carnitin
EP3593785A4 (de) Dentale zusammensetzung und herstellungsverfahren dafür
EP3760191A4 (de) Pharmazeutische zusammensetzung, herstellungsverfahren dafür sowie verwendung davon
EP3456711A4 (de) Caspase-hemmer und pharmazeutische zusammensetzung, verwendung und therapeutisches verfahren dafür
EP3760616A4 (de) 4-methyldihydropyrimidinonverbindung und medizinische verwendung davon
IL282999A (en) 4,3,1-oxadiazolone compound and drug
EP4076485A4 (de) Mit polyphenolischen verbindungen angereicherte extrakte und verwandte verfahren
EP4056683A4 (de) Hirnorganoid und seine verwendung
EP3813842A4 (de) Pharmazeutische zusammensetzung und herstellungsverfahren dafür
EP3765081A4 (de) Antimikrobielle fotosensibilisatorzusammensetzung und verfahren
EP3773541A4 (de) Isotopisch modifizierte zusammensetzung und deren therapeutische verwendung
EP3244884A4 (de) Intravenöse formulierungen von baclofen und behandlungsverfahren

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200921

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TABUTEAU, HERRIOT

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40041795

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20220216

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20220210BHEP

Ipc: A61P 25/30 20060101ALI20220210BHEP

Ipc: A61P 25/28 20060101ALI20220210BHEP

Ipc: A61P 25/24 20060101ALI20220210BHEP

Ipc: A61P 25/18 20060101ALI20220210BHEP

Ipc: A61P 25/00 20060101ALI20220210BHEP

Ipc: A61K 31/485 20060101ALI20220210BHEP

Ipc: A61K 31/137 20060101AFI20220210BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230306

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AXSOME THERAPEUTICS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS